Holen Sie sich die Stockscreener-App
2.56
4.92%
0.12
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Co-Chief Executive Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Director and Chief Operating Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics : Organisation and personnel changes Form 6 K - Marketscreener.com
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St
CytoMed Therapeutics : Update on Clinical Milestone CytoMed Therapeutics Announces First Patient Dosed in its First in Human Phase I Clinical Trial of Allogeneic CAR Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematologica - Marketscreener.com
CytoMed Therapeutics Limited Announces First Patient Dosed in Its First-In-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Marketscreener.com
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks
CytoMed begins clinical trial for innovative cancer therapy - Investing.com
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com
Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks
CytoMed Launches Innovative CAR-T Cell Trial - TipRanks
CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa
CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan
CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance
Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire
CytoMed Therapeutics Limited acquired the licence and certain assets of Cellsafe International Sdn Bhd from Cellsafe Biotech Group for MYR 2.3 million. - Marketscreener.com
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire
CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World
CytoMed Therapeutics Ltd (GDTC) Stock: A Comprehensive 52-Week Review - The InvestChronicle
CytoMed Therapeutics Acquires Cord Blood Banking Licence - GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
CytoMed Therapeutics Limited Announces Board and Audit Committee Changes - Marketscreener.com
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off ... - Quantisnow
CytoMed Therapeutics to Ring Nasdaq Closing Bell - Quantisnow
CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering - Quantisnow
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Quantisnow
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has ... - Quantisnow
Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2031 - InsightAce Analytic
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Yahoo Finance
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - Marketscreener.com
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire
Healthcare Stocks Moving Wednesday: OGEN, FEMY, JSPR, ABEO, GDTC, CING, HUMA, NEXI - InvestorsObserver
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PR Newswire
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
Cytomed Therapeutics Limited (GDTC-Q) QuotePress Release - The Globe and Mail
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - 팜뉴스
Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US - PR Newswire
CytoMed and MD Anderson partner to use gdTc for cancer treatment - Pharmaceutical Technology
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology - PR Newswire
Peter Choo-backed biomed firm CytoMed lists on Nasdaq - The Edge Singapore
GDTC IPO NewsSingapore-based cancer biotech CytoMed Therapeutics prices US IPO at $4 low end - Renaissance Capital
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering - PR Newswire
CARISMA Therapeutics (NASDAQ:CARM) Stock Quotes, Forecast and News Summary - Benzinga
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):